France's Exosens Q3 revenue jumps on strong  demand, rapid capacity ramp-up

By Reuters News


Overview

  • France-based imaging tech firm's Q3 revenue grew 23.5%, with 9M revenue up 18% yr/yr

  • Company confirms upgraded 2026 outlook for about 20% revenue growth and 25% adjusted EBITDA growth

  • Adjusted gross margin rose 16.1% yr/yr, but margin rate declined due to product mix and staffing costs


Outlook

  • Exosens expects 2026 revenue between €558 mln and €570 mln

  • Company sees 2026 adj EBITDA between €186 mln and €192 mln

  • Capital expenditure for 2026 expected at around 9% of revenue, excluding capitalized R&D


Result Drivers

  • DEFENSE AND SURVEILLANCE DEMAND - Co said revenue growth was driven by increased demand for night vision and imaging solutions in defense, surveillance, and nuclear instrumentation markets

  • CAPACITY RAMP-UP - Faster-than-expected ramp-up of European production capacity enabled higher sales volumes, supporting Q3 revenue growth

  • DRONE AND NUCLEAR MARKETS - Accelerating demand for imaging solutions in drone, counter-drone and nuclear applications contributed to segment growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

EUR 386.90 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the aerospace & defense peer group is "buy"

  • Wall Street's median 12-month price target for Exosens SA is €69.00, about 15.7% above its October 26 closing price of €59.65

  • The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 28 three months ago


Reuters Recommended Reads

  • Oct 26 - Boeing forecast to post small quarterly loss despite recent wins, analysts say

  • Oct 26 - India approves in principle $22 billion in military purchases

  • Oct 26 - Thales opens sonar site in Sydney to supply Australian armed forces


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.